NCT05210530已完成1 期
An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 3
- 主要终点
- Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.
研究概览
简要总结
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
详细描述
VCTX210A combination product (unit) comprises 2 components: (1) allogeneic pancreatic endoderm cells (PEC210A) genetically modified using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) to promote immune evasiveness and survival, and (2) a durable, removable, perforated device designed to deliver and retain the PEC210A cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.
时间窗: From implantation up to 6 months post implantation
次要结局
- The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.(From implantation up to 6 months post implantation)
- Qualitative evaluation of immune response to VCTX210A units assessed by histological staining for markers of host innate immune cells within the graft.(From implantation up to 6 months post implantation)
- Qualitative evaluation of immune response to VCTX210A units assessed by histological staining for markers of host adaptive immune cells within the graft.(From implantation up to 6 months post implantation)
- Incidence of new alloreactive antibodies found in the blood of patients post implantation.(From implantation up to 6 months post implantation)
- Incidence of new autoreactive antibodies found in the blood of patients post implantation.(From implantation up to 6 months post implantation)
- The percentage of viable graft cells per unit using immunohistochemical staining.(From implantation up to 6 months post implantation)
研究者
研究点 (3)
Loading locations...
相似试验
撤回
1 期
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid TumorsPancreas CancerSolid TumorGastric CancerNCT05181865Flame Biosciences
终止
1 期
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid TumorsSolid TumorsNCT05387265CytomX Therapeutics83
招募中
1 期
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1DGlucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes MellitusDiabetes Mellitus, Type 1NCT05565248CRISPR Therapeutics AG40
进行中（未招募）
1 期
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesCancerLung CancerNCT06577987Circle Pharma220
终止
1 期
A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsAdvanced Solid TumorsHematologic MalignanciesMultiple MyelomaLymphomaNCT04214093AstraZeneca9